Was Bruce C. Cozadd’s Jazz Pharmaceuticals (JAZZ) share sale a discretionary trade?

The sale was not a discretionary trade. It was executed automatically under a Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing and amount were pre-scheduled in advance.

What is the significance of the Rule 10b5-1 plan in Bruce C. Cozadd’s JAZZ share sale?

The Rule 10b5-1 plan indicates the sale was pre-arranged and executed automatically. This structure reduces the significance of trade timing, as it was set on November 26, 2025, rather than decided at the moment of sale.

Jazz Pharmaceuticals (JAZZ) director sells 6,000 shares in pre-set Rule 10b5-1 trade

Q: How many Jazz Pharmaceuticals (JAZZ) shares does Bruce C. Cozadd hold after this sale?

After the reported sale, Bruce C. Cozadd directly holds 372,682 Ordinary Shares of Jazz Pharmaceuticals. This figure reflects his position immediately following the 6,000-share open-market sale disclosed in the Form 4.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 Ordinary Shares of JAZZ in an open-market transaction. The shares were sold at an average price of $235.12 per share. After this sale, he directly holds 372,682 Ordinary Shares of Jazz Pharmaceuticals.

The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the transaction timing was scheduled in advance and was not a discretionary trade by the reporting person.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares ($1,410,720)

Net Sell 1 txn

Insider COZADD BRUCE C

Role null

Sold 6,000 shs ($1.41M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	6,000	$235.12	$1.41M

Holdings After Transaction: Ordinary Shares — 372,682 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 6,000 shares Sale price: $235.12 per share Shares held after sale: 372,682 shares +2 more

5 metrics

Shares sold 6,000 shares Open-market sale of Ordinary Shares

Sale price $235.12 per share Average price for 6,000-share sale

Shares held after sale 372,682 shares Direct ownership following transaction

Transaction date June 1, 2026 Date of open-market sale

Plan adoption date November 26, 2025 Rule 10b5-1 trading plan adoption

Key Terms

Rule 10b5-1, open-market sale, Form 4, Ordinary Shares

4 terms

Rule 10b5-1 regulatory

"plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action: "open-market sale" for 6,000 Ordinary Shares at $235.12 per share"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Ordinary Shares financial

"security_title: "Ordinary Shares" and total_shares_following_transaction: 372,682.0000"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 05:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/01/2026		S⁽¹⁾		6,000	D	$235.12	372,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Bruce C. Cozadd?

Jazz Pharmaceuticals reported that director Bruce C. Cozadd sold 6,000 Ordinary Shares. The shares were sold in an open-market transaction at an average price of $235.12 per share, as disclosed in the Form 4 filing.

How many Jazz Pharmaceuticals (JAZZ) shares does Bruce C. Cozadd hold after this sale?

After the reported sale, Bruce C. Cozadd directly holds 372,682 Ordinary Shares of Jazz Pharmaceuticals. This figure reflects his position immediately following the 6,000-share open-market sale disclosed in the Form 4.

At what price were Bruce C. Cozadd’s Jazz Pharmaceuticals (JAZZ) shares sold?

The 6,000 Jazz Pharmaceuticals Ordinary Shares were sold at an average price of $235.12 per share. This price represents the transaction value reported for the open-market sale on the Form 4.

Did the Form 4 for Jazz Pharmaceuticals (JAZZ) include any derivative transactions for Bruce C. Cozadd?

No derivative transactions were reported for Bruce C. Cozadd in this Form 4. The filing shows only a single non-derivative open-market sale of 6,000 Ordinary Shares and no remaining derivative positions in the derivative summary.